Stockscreener 앱 받기
23.11
0.94%
-0.22
시장 영업 전:
23.16
0.05
+0.22%
전일 마감가:
$23.33
열려 있는:
$23.49
하루 거래량:
636.22K
Relative Volume:
0.53
시가총액:
$2.62B
수익:
$6.94M
순이익/손실:
$-212.39M
주가수익비율:
-9.5181
EPS:
-2.428
순현금흐름:
$-200.60M
1주 성능:
-2.53%
1개월 성능:
+5.82%
6개월 성능:
+50.55%
1년 성능:
+171.88%
1일 변동 폭
$22.46
$24.01
1주일 범위
$22.16
$24.01
52주 변동 폭
$7.15
$27.65
이뮤놈 Stock (IMNM) Company Profile
명칭
Immunome Inc
전화
610-321-3700
주소
18702 N. CREEK PARKWAY, BOTHELL
Compare IMNM vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IMNM
Immunome Inc
|
23.11 | 2.64B | 6.94M | -212.39M | -200.60M | -2.428 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
이뮤놈 Stock (IMNM) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-12 | 개시 | H.C. Wainwright | Buy |
| 2025-12-01 | 개시 | Truist | Buy |
| 2025-09-22 | 개시 | Goldman | Buy |
| 2025-09-05 | 개시 | Craig Hallum | Buy |
| 2025-04-02 | 개시 | Lake Street | Buy |
| 2024-11-08 | 개시 | Stephens | Overweight |
| 2024-05-31 | 개시 | Piper Sandler | Overweight |
| 2024-04-30 | 개시 | JP Morgan | Overweight |
| 2024-04-15 | 개시 | Guggenheim | Buy |
| 2024-01-29 | 개시 | Leerink Partners | Outperform |
| 2023-12-19 | 개시 | Wedbush | Outperform |
| 2021-10-29 | 개시 | Cantor Fitzgerald | Overweight |
모두보기
이뮤놈 주식(IMNM)의 최신 뉴스
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Joplin Globe
Why (IMNM) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Analysts Have Conflicting Sentiments on These Healthcare Companies: Amgen (AMGN), Immunome (IMNM) and Resmed (RMD) - The Globe and Mail
Lake Street Maintains Immunome(IMNM.US) With Buy Rating, Maintains Target Price $30 - Moomoo
Universal Beteiligungs und Servicegesellschaft mbH Acquires New Position in Immunome, Inc. $IMNM - MarketBeat
Immunome Announces Submission of New Drug Application to U.S. FDA for Varegacestat for the Treatment of Adults with Desmoid Tumors - BioSpace
Immunome (IMNM) Submits NDA for Varegacestat to Treat Desmoid Tu - GuruFocus
Craig-Hallum Maintains Immunome(IMNM.US) With Buy Rating, Maintains Target Price $36 - Moomoo
Immunome submits drug application for desmoid tumor treatment - Investing.com
Immunome submits drug application for desmoid tumor treatment By Investing.com - Investing.com South Africa
Immunome (IMNM) FDA Approvals, PDUFA Dates & Drug Alerts 2026 - MarketBeat
Why is IMNM stock rising today? - MSN
Immunome prices $400M stock offering at $21.50 a share - MSN
The Bull Case For Immunome (IMNM) Could Change Following Varegacestat’s ASCO 2026 Spotlight And NDA Timeline – Learn Why - simplywall.st
A Look At Immunome (IMNM) Valuation As Varegacestat Nears ASCO 2026 Spotlight And FDA NDA Filing - Yahoo Finance
[ARS] Immunome Inc. SEC Filing - Stock Titan
Immunome (IMNM) 2026 proxy: trial success, executive pay and key stockholder votes - Stock Titan
Immunome Desmoid Tumor Data And NDA Plan Test Growth Expectations - simplywall.st
Immunome (IMNM) Long-Term View | Immunome Inc. 23.8% EPS Miss, No Revenue EstimateMiss Estimates - Cổng thông tin điện tử tỉnh Lào Cai
Immunome Announces Oral Presentation of Phase 3 RINGSIDE Data at 2026 ASCO Annual Meeting - BioSpace
Immunome’s desmoid tumor trial data selected for ASCO presentation By Investing.com - Investing.com Australia
Understanding Momentum Shifts in (IMNM) - Stock Traders Daily
Immunome’s desmoid tumor trial data selected for ASCO presentation - Investing.com
Immunome (IMNM) Stock: Buy, Sell, Hold? (Market Focus) 2026-04-20Pre Earnings - Cổng thông tin điện tử Tỉnh Sơn La
Is institutional money buying Immunome (IMNM) stock (+5.89%) 2026-04-18Certified Trade Ideas - UBND thành phố Hải Phòng
Analysts Offer Insights on Healthcare Companies: GE Healthcare Technologies Inc (GEHC), Immunome (IMNM) and Eli Lilly & Co (LLY) - The Globe and Mail
Piper Sandler Maintains Immunome(IMNM.US) With Buy Rating, Maintains Target Price $33 - 富途牛牛
Immunome, Inc. (IMNM) Stock Analysis: Exploring a 52.79% Potential Upside with Strong Buy Consensus - DirectorsTalk Interviews
IMNM News | IMMUNOME INC (NASDAQ:IMNM) - ChartMill
JPMorgan Chase & Co. Cuts Stock Holdings in Immunome, Inc. $IMNM - MarketBeat
Immunome, Inc. (NASDAQ:IMNM) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Immunome (IMNM) Price Forecast: Breakout Points to Higher Highs Ahead - FXEmpire
Death Cross: Can Immunome Inc be the next market leader2026 Technicals & Fast Exit/Entry Strategy Plans - baoquankhu1.vn
Stock Analysis: Is Immunome Inc part of any ETF2026 Retail Activity & Daily Volume Surge Signals - baoquankhu1.vn
Avoiding Lag: Real-Time Signals in (IMNM) Movement - Stock Traders Daily
Death Cross: Is Immunome Inc gaining market share2026 Key Lessons & Technical Pattern Based Buy Signals - baoquankhu1.vn
LifeSci Capital Maintains Immunome(IMNM.US) With Buy Rating, Maintains Target Price $40 - Moomoo
Is Immunome (IMNM) Stock Expanding | Price at $22.19, Up 1.60%Bullish Pattern - Xã Thanh Hà
Immunome CSO Sells Shares: Transaction Details & Company SnapshotNews and Statistics - IndexBox
Immunome (IMNM) Is Up 11.4% After CEO Share Buy And Positive Phase III DataWhat's Changed - Sahm
Immunome's Chief Scientist Trimmed His Stake. A Planned FDA Submission Tells You More - AOL.com
Insider Sell: What is the long term forecast for Immunome Inc stockDividend Hike & Stepwise Entry/Exit Trade Alerts - baoquankhu1.vn
Immunome's Chief Scientist Trimmed His Stake. A Planned FDA Submission Tells You More - The Motley Fool
A Look At Immunome (IMNM) Valuation After Oncology Progress EPS Upgrades And CEO Insider Buying - Sahm
Immunome, Inc. (IMNM) stock price, news, quote and history - Yahoo Finance Singapore
Immunome Inc (IMNM) CSO Higgins sells $204,238 in stock By Investing.com - Investing.com South Africa
Immunome CFO Rosett sells $1.4m in shares By Investing.com - Investing.com Canada
Immunome Inc (IMNM) CSO Higgins sells $204,238 in stock - Investing.com
이뮤놈 (IMNM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.14%
0.48%
자본화:
|
볼륨(24시간):